|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000089692 |
Summary for LAG3 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000089692 | Gene symbol | LAG3 |
| Gene name | lymphocyte activating 3 | |
| HGNC | 6476 | |
| Entrez ID | 3902 | |
| Gene type | protein_coding | |
| Synonyms | LAG3|CD223 | |
| UniProtAcc | P18627 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for LAG3 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| LAG3 | 4.70e+02 | 1.51e+00 | 6.09e-01 | 2.49e+00 | 1.28e-02 | 2.94e-02 | BLCA |
| LAG3 | 4.60e+02 | 1.35e+00 | 5.03e-01 | 2.68e+00 | 7.42e-03 | 3.00e-02 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| LAG3 | 2.79e+02 | -1.15e+00 | 2.90e-01 | -3.95e+00 | 7.68e-05 | 1.89e-04 | THCA |
| LAG3 | 5.14e+02 | 1.21e+00 | 3.06e-01 | 3.97e+00 | 7.20e-05 | 2.05e-04 | LUSC |
| LAG3 | 3.44e+02 | 1.99e+00 | 1.55e-01 | 1.28e+01 | 9.40e-38 | 6.33e-37 | BRCA |
Top |
Sex-biased somatic mutation for LAG3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for LAG3 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| CHOL | cg22777668 | chr12:6772137 | CGI:chr12:6773689-6773940 | promoter | 5.91e-01 | 4.87e-01 | 2.01e+00 | 4.49e-02 | 4.72e-02 | 1.04e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg16352928 | chr12:6772424 | CGI:chr12:6773689-6773940 | promoter | 6.68e-01 | 8.01e-01 | -5.18e+00 | 2.22e-07 | 9.88e-07 | -1.32e-01 |
| BLCA | cg01820374 | chr12:6772917 | CGI:chr12:6773689-6773940 | promoter,exon,gene body | 4.26e-01 | 5.27e-01 | -2.78e+00 | 5.36e-03 | 8.60e-03 | -1.02e-01 |
| LIHC | cg10191002 | chr12:6773958 | CGI:chr12:6773689-6773940 | promoter,exon,CDS,gene body | 6.50e-01 | 5.48e-01 | 5.04e+00 | 4.77e-07 | 1.97e-06 | 1.02e-01 |
| LIHC | cg19421125 | chr12:6773690 | CGI:chr12:6773689-6773940 | promoter,gene body | 7.79e-01 | 6.70e-01 | 4.53e+00 | 6.03e-06 | 1.76e-05 | 1.09e-01 |
| ESCA | cg10191002 | chr12:6773958 | CGI:chr12:6773689-6773940 | promoter,exon,CDS,gene body | 4.74e-01 | 3.06e-01 | 2.49e+00 | 1.27e-02 | 3.73e-02 | 1.69e-01 |
| ESCA | cg19421125 | chr12:6773690 | CGI:chr12:6773689-6773940 | promoter,gene body | 5.57e-01 | 2.86e-01 | 3.09e+00 | 2.02e-03 | 3.37e-02 | 2.72e-01 |
| CHOL | cg10500147 | chr12:6772435 | CGI:chr12:6773689-6773940 | promoter | 5.46e-01 | 1.90e-01 | 2.88e+00 | 4.04e-03 | 1.47e-02 | 3.56e-01 |
| CHOL | cg17213699 | chr12:6772458 | CGI:chr12:6773689-6773940 | promoter | 7.19e-01 | 4.88e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.31e-01 |
| CHOL | cg19872463 | chr12:6772463 | CGI:chr12:6773689-6773940 | promoter | 7.09e-01 | 4.33e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.76e-01 |
| CHOL | cg26956535 | chr12:6771474 | CGI:chr12:6773689-6773940 | promoter | 9.36e-01 | 8.20e-01 | 3.24e+00 | 1.18e-03 | 1.07e-02 | 1.16e-01 |
| CHOL | cg22777668 | chr12:6772137 | CGI:chr12:6773689-6773940 | promoter | 4.87e-01 | 2.18e-01 | 3.10e+00 | 1.96e-03 | 1.07e-02 | 2.69e-01 |
| CHOL | cg16352928 | chr12:6772424 | CGI:chr12:6773689-6773940 | promoter | 6.62e-01 | 3.50e-01 | 3.02e+00 | 2.51e-03 | 1.19e-02 | 3.12e-01 |
| CHOL | cg02695343 | chr12:6772429 | CGI:chr12:6773689-6773940 | promoter | 6.25e-01 | 3.76e-01 | 3.10e+00 | 1.96e-03 | 1.07e-02 | 2.49e-01 |
| CHOL | cg01820374 | chr12:6772917 | CGI:chr12:6773689-6773940 | promoter,exon,gene body | 5.33e-01 | 2.88e-01 | 2.95e+00 | 3.19e-03 | 1.32e-02 | 2.46e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| THCA | cg16352928 | chr12:6772424 | CGI:chr12:6773689-6773940 | promoter | 7.75e-01 | 6.61e-01 | 5.90e+00 | 3.63e-09 | 4.94e-08 | 1.14e-01 |
| HNSC | cg22777668 | chr12:6772137 | CGI:chr12:6773689-6773940 | promoter | 3.96e-01 | 2.74e-01 | 3.19e+00 | 1.42e-03 | 9.21e-03 | 1.22e-01 |
| LIHC | cg26956535 | chr12:6771474 | CGI:chr12:6773689-6773940 | promoter | 8.86e-01 | 7.48e-01 | 5.46e+00 | 4.65e-08 | 1.75e-06 | 1.38e-01 |
| LIHC | cg22777668 | chr12:6772137 | CGI:chr12:6773689-6773940 | promoter | 3.58e-01 | 2.19e-01 | 4.62e+00 | 3.77e-06 | 3.39e-05 | 1.39e-01 |
| KIRP | cg17213699 | chr12:6772458 | CGI:chr12:6773689-6773940 | promoter | 8.41e-01 | 9.49e-01 | -3.07e+00 | 2.13e-03 | 6.18e-03 | -1.08e-01 |
Top |
Exon skipping events with PSI in TCGA for LAG3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for LAG3 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for LAG3 |
| TFs related to LAG3. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LAG3 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for LAG3 |
| RBPs related to ES in LAG3. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LAG3 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7966903 | chr12:15033030:G:A | - | 0.200330293177839 | 0.00223619008474085 | LIHC | Female-baised eQTL |
| rs79864833 | chr12:15030195:A:C | - | 0.195885241368397 | 0.00233584824376338 | LIHC | Female-baised eQTL |
| rs76729577 | chr12:15030370:G:A | - | 0.195885241368397 | 0.00233584824376338 | LIHC | Female-baised eQTL |
| rs79961888 | chr12:15029376:G:A | - | 0.198703654303786 | 0.0117892713013658 | LIHC | Female-baised eQTL |
| rs77682678 | chr12:15029837:G:A | - | 0.198703654303786 | 0.0117892713013658 | LIHC | Female-baised eQTL |
| rs75656216 | chr12:15022250:G:A | - | 0.174021802684865 | 0.0124519240277512 | LIHC | Female-baised eQTL |
| rs2430717 | chr12:14963394:G:C | - | -0.184333385494907 | 0.0269060685012813 | LIHC | Female-baised eQTL |
| rs1379488 | chr12:566961:G:A | - | 0.233480316069611 | 0.0397361247844835 | LIHC | Female-baised eQTL |
| rs148788419 | chr12:14990276:C:T | - | 0.17353604131258 | 0.0435184664608065 | LIHC | Female-baised eQTL |
| rs12823426 | chr12:5143964:A:T | - | 0.1255587567765 | 0.0466616347393751 | LIHC | Female-baised eQTL |
| rs2109186 | chr12:5140981:C:T | - | 0.125093109318638 | 0.0495175133964171 | LIHC | Female-baised eQTL |
| rs2268122 | chr12:13744527:G:T | - | 0.127076857734086 | 0.0350807811361033 | LUSC | Female-baised eQTL |
| rs11053499 | chr12:9895466:A:C | - | 0.176910930955308 | 0.0469681078861238 | LUSC | Female-baised eQTL |
| rs4326887 | chr12:10223289:T:G | - | -0.136815516094617 | 0.0475484332345988 | LUSC | Female-baised eQTL |
| rs12231503 | chr12:9904795:G:A | - | 0.181644151613881 | 0.0482638639702537 | LUSC | Female-baised eQTL |
| rs41421844 | chr12:13237090:T:C | - | 0.0799572019214591 | 0.00199455377634741 | LUAD | Female-baised eQTL |
| rs7296793 | chr12:14480511:A:T | - | 0.0820093498991789 | 0.017405387211316 | LUAD | Female-baised eQTL |
| rs117545050 | chr12:14486063:C:T | - | 0.0892823373814353 | 0.0175096776037916 | LUAD | Female-baised eQTL |
| rs2007044 | chr12:2235794:A:G | - | 0.0476393762789517 | 0.025187754619227 | LUAD | Female-baised eQTL |
| rs882195 | chr12:2241235:G:C | - | 0.0456024430846108 | 0.0266849428481997 | LUAD | Female-baised eQTL |
| rs554447 | chr12:5103761:C:T | - | 0.0526030466494323 | 0.0476416921126852 | LUAD | Female-baised eQTL |
| rs11055699 | chr12:13975902:C:T | - | 0.0848431210551615 | 0.00317299346825169 | COAD | Female-baised eQTL |
| rs7138947 | chr12:5509782:C:A | - | 0.0534721634570474 | 0.0172403425861579 | COAD | Female-baised eQTL |
| rs73066181 | chr12:11870909:C:A | - | 0.103197575455634 | 0.023666147944934 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs79169584 | chr12:15416230:G:A | - | 0.0769823954827501 | 0.0479218899550801 | LIHC | Male-baised eQTL |
| rs17833759 | chr12:13696524:A:C | - | 0.0853569386973222 | 0.0128225899508151 | BLCA | Male-baised eQTL |
| rs11615510 | chr12:13666989:A:G | - | 0.0823659709417397 | 0.0393545872238021 | BLCA | Male-baised eQTL |
| rs11608451 | chr12:13667381:T:C | - | 0.0823659709417397 | 0.0393545872238021 | BLCA | Male-baised eQTL |
| rs12817623 | chr12:13482957:A:G | - | 0.0768788289220863 | 0.0473005217502631 | LUAD | Male-baised eQTL |
| rs1805483 | chr12:13612304:A:T | - | 0.0420902986782137 | 0.0250625194562751 | COAD | Male-baised eQTL |
| rs2889504 | chr12:7855536:C:A | - | 0.0801633781039151 | 0.0376762116755202 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000089692 |
| CpG Site: cg19872463 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.090365265471967 | |
 | Gene ID: ENSG00000089692 |
| CpG Site: cg17213699 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.0971857715186348 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg19872463 | chr12:6772463 | promoter | -0.090365265471967 | 1.26809752964362e-05 | -0.3405090288574465 | 2.427863628516836e-08 | LUAD |
| cg17213699 | chr12:6772458 | promoter | -0.0971857715186348 | 1.36742440928674e-05 | -0.33910144136601605 | 2.7946745358277444e-08 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of LAG3 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
